Study S001736

Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients: a Randomized, Parallel Controlled Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06217887
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 58
Start: 2020-05-10
Primary completion: 2024-02
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions: Type 2 Diabetes Mellitus; Cognitive Function Abnormal
Interventions: DRUG:loxenatide Group; DRUG:Gliclazide Group
Results posted: FALSE

Registered primary outcomes

Change of olfactory brain activation by fMRI [from baseline to 4-month follow-up]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022403	Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Cheng H, Diabetes care	2022	Randomized trial	PMID 35263425 DOI	registry reference BACKGROUND:35263425
R0011068	Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Zhang Z, Diabetes care	2019	Other	PMID 31221697 DOI	registry reference BACKGROUND:31221697